Omics-Based Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design, By Indication, By Region, And Segment Forecasts, 2022 - 2030

Table of content

Chapter 1 Research Methodology
1.1 Market Segmentation & Scope
1.2 Market Definition
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources & third party perspectives
1.3.4 Primary research
1.4 Information Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Data Visualization
1.6 Data Validation & Publishing
Chapter 2 Executive Summary
2.1 Omics-based Clinical Trials Market Outlook, 2018 - 2030
Chapter 3 Industry Outlook: Market Variables, Trends, & Scope
3.1 Penetration &Growth Prospect Mapping For Omics-based Clinical Trials, 2018
3.2 Trend Analysis
3.2.1 Source trend
3.2.2 Service trend
3.2.3 Product trend
3.2.4 Regional trend
3.3 Omics-based Clinical Trials Market: Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 Rising investment by major pharmaceutical companies
3.3.1.2 Shift towards personalized medicine
3.3.1.3 Growing prevalence of chronic disorders
3.3.1.4 Increasing partnership and collaboration
3.3.2 Market restraint analysis
3.3.2.1 Rising costs of clinical trials
3.4 Key Opportunity Analysis
3.4.1 Mergers & acquisitions for facility expansion
3.4.2 Growing demand for omics approaches for clinical trials
3.5 Industry Analysis - Porter’s
3.5.1 Supplier Power: Substantial number of suppliers for bioprocessing equipment contributes to the low supplier power
3.5.2 Buyer Power: Fragmented nature of biopharmaceutical industry has led to moderate bargaining power of buyers
3.5.3 Substitution Threat: High due to presence of several big pharma companies
3.5.4 New Entrants Threat: Presence of established players coupled with need of adequate capacity results in moderate threat of new entrants
3.5.5 Competitive Rivalry: High due to the rising number of small players in the market
3.6 Omics-based Clinical Trials-SWOT Analysis, By PEST
3.6.1 Political landscape
3.6.2 Economic landscape
3.6.3 Social landscape
3.6.4 Technology landscape
3.7 Omics-based Clinical Trials Market: Company Share Analysis
3.8 Competitive Landscape
3.8.1 Strategy Framework
3.8.2 Company Categorization
3.8.3 New Entrants
3.8.4 Mature Players & Leaders
3.9 Trends In Pharmaceutical Industry
3.10 R&D Landscape Of Pharmaceutical
3.11 COVID-19 Impact Analysis
Chapter 4 Omics-based Clinical Trials Market: Phase Estimates & Trend Analysis
4.1 Global Omics-based Clinical Trials Market: Phase Movement Analysis
4.2 Phase I
4.2.1 Global phase I market, 2018 - 2030 (USD Million)
4.3 Phase II
4.3.1 Global phase II market, 2018 - 2030 (USD Million)
4.4 Phase III
4.4.1 Global phase III market, 2018 - 2030 (USD Million)
4.5 Phase IV
4.5.1 Global phase IV market, 2018 - 2030 (USD Million)
Chapter 5 Omics-based Clinical Trials Market: Study Design Estimates & Trend Analysis
5.1 Global Omics-based Clinical Trials Market: Study Design Movement Analysis
5.2 Interventional Studies
5.2.1 Global interventional market, 2018 - 2030 (USD Million)
5.3 Observational Studies
5.3.1 Global observational studies market, 2018 - 2030 (USD Million)
5.4 Expanded Access Studies
5.4.1 Global expanded access studies market, 2018 - 2030 (USD Million)
Chapter 6 Omics-based Clinical Trials Market: Indication Estimates & Trend Analysis
6.1 Global Omics-based Clinical Trials Market: Indication Movement Analysis
6.2 Oncology
6.2.1 Global oncology market, 2018 - 2030 (USD Million)
6.3 Cardiology
6.3.1 Global cardiology market, 2018 - 2030 (USD Million)
6.4 Respiratory Diseases
6.4.1 Global respiratory diseases market, 2018 - 2030 (USD Million)
6.5 Skin Diseases
6.5.1 Global skin diseases market, 2018 - 2030 (USD Million)
6.6 CNS Disorders
6.6.1 Global CNS disorders market, 2018 - 2030 (USD Million)
6.7 Immunology
6.7.1 Global Immunology market, 2018 - 2030 (USD Million)
6.8 Genetic Disorders (includes the rare diseases)
6.8.1 Global genetic disorders (includes the rare diseases) market, 2018 - 2030 (USD Million)
6.9 Others (includes ophthalmic , ear diseases, etc)
6.9.1 Global others (includes opthalmic, ear diseases, etc) market, 2018 - 2030 (USD Million)
Chapter 7 Omics-based Clinical Trials Market: Regional Estimates & Trend Analysis, by Phase, Study Design, & Indication
7.1 Omics-based Clinical Trials Market Share By Region, 2021 & 2030
7.2 North America
7.2.1 North America Omics-based Clinical Trials market, 2018 - 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Omics-based Clinical Trials market, by phase, 2018 - 2030 (USD Million)
7.2.2.2 U.S. Omics-based Clinical Trials market, by study design, 2018 - 2030 (USD Million)
7.2.2.3 U.S. Omics-based Clinical Trials market, by indication, 2018 - 2030 (USD Million)
7.2.3 Canada
7.2.3.1 Canada Omics-based Clinical Trials market, by phase, 2018 - 2030 (USD Million)
7.2.3.2 Canada Omics-based Clinical Trials market, by study design, 2018 - 2030 (USD Million)
7.2.3.3 Canada Omics-based Clinical Trials market, by indication, 2018 - 2030 (USD Million)
7.3 Europe
7.3.1 Europe Omics-based Clinical Trials market, 2018 - 2030 (USD Million)
7.3.2 U.K.
7.3.2.1 U.K. Omics-based Clinical Trials market, by phase, 2018 - 2030 (USD Million)
7.3.2.2 U.K. Omics-based Clinical Trials market, by study design, 2018 - 2030 (USD Million)
7.3.2.3 U.K. Omics-based Clinical Trials market, by indication, 2018 - 2030 (USD Million)
7.3.3 Germany
7.3.3.1 Germany Omics-based Clinical Trials market, by phase, 2018 - 2030 (USD Million)
7.3.3.2 Germany Omics-based Clinical Trials market, by study design, 2018 - 2030 (USD Million)
7.3.3.3 Germany Omics-based Clinical Trials market, by indication, 2018 - 2030 (USD Million)
7.3.4 France
7.3.4.1 France Omics-based Clinical Trials market, by phase, 2018 - 2030 (USD Million)
7.3.4.2 France Omics-based Clinical Trials market, by study design, 2018 - 2030 (USD Million)
7.3.4.3法国Omics-based临床试验市场,by indication, 2018 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Omics-based Clinical Trials market, 2018 - 2030 (USD Million)
7.4.2 China
7.4.2.1 China Omics-based Clinical Trials market, by phase, 2018 - 2030 (USD Million)
7.4.2.2 China Omics-based Clinical Trials market, by study design, 2018 - 2030 (USD Million)
7.4.2.3 China Omics-based Clinical Trials market, by indication, 2018 - 2030 (USD Million)
7.4.3 Japan
7.4.3.1 Japan Omics-based Clinical Trials market, by phase, 2018 - 2030 (USD Million)
7.4.3.2 Japan Omics-based Clinical Trials market, by study design, 2018 - 2030 (USD Million)
7.4.3.3 Japan Omics-based Clinical Trials market, by indication, 2018 - 2030 (USD Million)
7.4.4 India
7.4.4.1 India Omics-based Clinical Trials market, by phase, 2018 - 2030 (USD Million)
7.4.4.2 India Omics-based Clinical Trials market, by study design, 2018 - 2030 (USD Million)
7.4.4.3 India Omics-based Clinical Trials market, by indication, 2018 - 2030 (USD Million)
7.4.5 Australia
7.4.5.1 Australia Omics-based Clinical Trials market, by phase, 2018 - 2030 (USD Million)
7.4.5.2 Australia Omics-based Clinical Trials market, by study design, 2018 - 2030 (USD Million)
7.4.5.3 Australia Omics-based Clinical Trials market, by indication, 2018 - 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America Omics-based Clinical Trials market, 2018 - 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Omics-based Clinical Trials market, by phase, 2018 - 2030 (USD Million)
7.5.2.2 Brazil Omics-based Clinical Trials market, by study design, 2018 - 2030 (USD Million)
7.5.2.3 Brazil Omics-based Clinical Trials market, by indication, 2018 - 2030 (USD Million)
7.5.3 Mexico
7.5.3.1 Mexico Omics-based Clinical Trials market, by phase, 2018 - 2030 (USD Million)
7.5.3.2 Mexico Omics-based Clinical Trials market, by study design, 2018 - 2030 (USD Million)
7.5.3.3 Mexico Omics-based Clinical Trials market, by indication, 2018 - 2030 (USD Million)
7.6 Middle East & Africa (MEA)
7.6.1 Middle East & Africa Omics-based Clinical Trials market, 2018 - 2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Omics-based Clinical Trials market, by phase, 2018 - 2030 (USD Million)
7.6.2.2 South Africa Omics-based Clinical Trials market, by study design, 2018 - 2030 (USD Million)
7.6.2.3 South Africa Omics-based Clinical Trials market, by indication, 2018 - 2030 (USD Million)
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Omics-based Clinical Trials market, by phase, 2018 - 2030 (USD Million)
7.6.3.2 Saudi Arabia Omics-based Clinical Trials market, by study design, 2018 - 2030 (USD Million)
7.6.3.3 Saudi Arabia Omics-based Clinical Trials market, by indication, 2018 - 2030 (USD Million)
7.6.4 UAE
7.6.4.1 UAE Omics-based Clinical Trials market, by phase, 2018 - 2030 (USD Million)
7.6.4.2 UAE Omics-based Clinical Trials market, by study design, 2018 - 2030 (USD Million)
7.6.4.3 UAE Omics-based Clinical Trials market, by indication, 2018 - 2030 (USD Million)
Chapter 8 Competitive Landscape
8.1 Company Profiles
8.1.1 Parexel International Corporation
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic initiatives
8.1.2 Pharmaceutical Product Development (PPD)
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic initiatives
8.1.3 Charles River Laboratory
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic initiatives
8.1.4 ICON plc
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Product benchmarking
8.1.4.4 Strategic initiatives
8.1.5 SGS SA
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Product benchmarking
8.1.5.4 Strategic initiatives
8.1.6 Eli Lilly and Company
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Product benchmarking
8.1.6.4 Strategic initiatives
8.1.7Pfizer Inc.
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Product benchmarking
8.1.7.4 Strategic initiatives
8.1.8 Merck & Co., Inc.
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Product benchmarking
8.1.8.4 Strategic initiatives
8.1.9 Covance Inc.
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Product benchmarking
8.1.9.4 Strategic initiatives
8.1.10 Novo Nordisk
8.1.10.1 Company overview
8.1.10.2 Financial performance
8.1.10.3 Product benchmarking
8.1.10.4 Strategic initiatives
8.1.11 Rebus Bio
8.1.11.1 Company overview
8.1.11.2 Financial performance
8.1.11.3 Product benchmarking
8.1.11.4 Strategic initiatives

List of Tables

TABLE 1 List of Secondary Sources
TABLE 2 List of Abbreviations
TABLE 3 Therapeutics in development
TABLE 4 Vaccines in development
表5为COVID-19疫苗的发展
TABLE 6 Impact of COVID-19 on other therapeutic areas
TABLE 7 Strategic collaborations by key players
TABLE 8 Top 10 therapy areas by phase

List of Figures

FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market segmentation & scope
FIG. 8 Pharmaceutical market outlook, 2018 - 2030
FIG. 9 Market trends & outlook
FIG. 10 Penetration & growth prospect mapping for omics-based clinical trials, 2021
FIG. 11 Market driver relevance analysis (Current & future impact)
FIG. 12 Market restraint relevance analysis (Current & future impact)
FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Company market share analysis
FIG. 16 Strategy framework
FIG. 17 Participant categorization
FIG. 18 Trends in biopharmaceutical industry
FIG. 19 R&D process of biopharmaceutical development
FIG. 20 Global omics-based clinical trials market: Phase outlook key takeaways
FIG. 21 Global omics-based clinical trials market: Phase movement analysis
FIG. 22 Global phase I market: Phase movement analysis
FIG. 23 Global phase II market: Phase movement analysis
FIG. 24 Global phase III market: Phase movement analysis
FIG. 25 Global phase IV market: Phase movement analysis
FIG. 26 Global omics-based clinical trials market: Study design outlook key takeaways
FIG. 27 Global omics-based clinical trials market: Study design movement analysis
FIG. 28 Global interventional studies market, 2018 - 2030 (USD Million)
FIG. 29 Global observational studies market, 2018 - 2030 (USD Million)
FIG. 30 Global expanded access studies market, 2018 - 2030 (USD Million)
FIG. 31 Global omics-based clinical trials market: Indication outlook key takeaways
图32全球临床试验omics-based市场:Indication movement analysis
FIG. 33 Global oncology market, 2018 - 2030 (USD Million)
FIG. 34 Global cardiology market, 2018 - 2030 (USD Million)
FIG. 35 Global respiratory diseases market, 2018 - 2030 (USD Million)
FIG. 36 Global skin diseases market, 2018 - 2030 (USD Million)
FIG. 37 Global CNS disorders market, 2018 - 2030 (USD Million)
FIG. 38 Global immunology market, 2018 - 2030 (USD Million)
FIG. 39 Global genetic diseases (includes the rare diseases) market, 2018 - 2030 (USD Million)
FIG. 40 Global others (includes opthalmic, eye diseases, etc) market, 2018 - 2030 (USD Million)
FIG. 41 Regional market place: Key takeaway
FIG. 42 Comparison of biopharmaceutical manufacturing facilities region and country wise
FIG. 43 Omics-based clinical trials regional outlook, 2020 & 2028
FIG. 44 North America omics-based clinical trials market, 2018 - 2030 (USD Million)
FIG. 45 U.S. omics-based clinical trials market, 2018 - 2030 (USD Million)
FIG. 46 Canada omics-based clinical trials market, 2018 - 2030 (USD Million)
FIG. 47 Europe omics-based clinical trials market, 2018 - 2030 (USD Million)
FIG. 48 U.K. omics-based clinical trials market, 2018 - 2030 (USD Million)
FIG. 49 Revenue growth of Germany pharmaceutical industry
FIG. 50 Germany omics-based clinical trials market, 2018 - 2030 (USD Million)
FIG. 51 France omics-based clinical trials market, 2018 - 2030 (USD Million)
FIG. 52 Asia Pacific omics-based clinical trials market, 2018 - 2030 (USD Million)
FIG. 53 China omics-based clinical trials market, 2018 - 2030 (USD Million)
FIG. 54 Japan omics-based clinical trials market, 2018 - 2030 (USD Million)
FIG. 55 India omics-based clinical trials market, 2018 - 2030 (USD Million)
FIG. 56 Australia omics-based clinical trials market, 2018 - 2030 (USD Million)
FIG. 57 Latin America omics-based clinical trials market, 2018 - 2030 (USD Million)
FIG. 58 Brazil omics-based clinical trials market, 2018 - 2030 (USD Million)
FIG. 59 Mexico omics-based clinical trials market, 2018 - 2030 (USD Million)
FIG. 60 Middle East & Africa omics-based clinical trials market, 2018 - 2030 (USD Million)
FIG. 61 South Africa omics-based clinical trials market, 2018 - 2030 (USD Million)
FIG. 62 Saudi Arabia omics-based clinical trials market, 2018 - 2030 (USD Million)
FIG. 63 UAE omics-based clinical trials market, 2018 - 2030 (USD Million)